---
category: news
title: "Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA, Darmstadt, Germany and Pfizer Inc."
excerpt: "Biodesix, Inc. announced initiation of the next phase of their biomarker development program with Merck KGaA, Darmstadt, Germany and Pfizer Inc., New York, NY. The companies have completed initial discovery and development of a new proteomic test that identifies likely responders to the anti-PD-L1 checkpoint inhibitor (BAVENCIOÂ®) (avelumab)."
publishedDateTime: 2020-02-11T11:00:00Z
webUrl: "https://www.marketwatch.com/press-release/biodesix-announces-initiation-of-clinical-phase-biomarker-development-program-with-merck-kgaa-darmstadt-germany-and-pfizer-inc-2020-02-11"
type: article
quality: 25
heat: 25
published: false

provider:
  name: MarketWatch
  domain: marketwatch.com
  images:
    - url: "/assets/images/organizations/marketwatch.com-50x50.jpg"
      width: 50
      height: 50

topics:
  - AI
  - AI in Healthcare

images:
  - url: "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png"
    width: 1200
    height: 630
    title: "Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA, Darmstadt, Germany and Pfizer Inc."

secured: "8duLy4+hpwFJzBRFYimcFhHrRkjRUCHraoA9fe0CxEQO+Zc1uxMCoEbAL043zyGC4r1HENUG+qsEGEP6WKKI8TK7wL6l/WttCUJNwbwEqdOklZG2nvA8+WVHYxZFDoN03KetzZ4C0pe94THuaZxvq1sZAN94C6+gcRNl+DzQiIXwO4OWzIoV9LM49F4LTxTC/WyYhKgDeLObbmrvYuIs9w+rfkzbKQH+s0wc3DqF/ly0VzppINJV0EFPZrvu8CrIqrzPCHaYClsf1a1ppZ0V5JYXp2nWV5b+0TDMgtweOSDqX6lu92gKM2dOOYi0gwaJ;7wYxr9Zj163NL/9vcXMlKw=="
---

